RecruitingNCT06863857

Dual-energy SPEctral CT to Evaluate Response to First-line Therapies in Patients With Metastatic Clear Cell REnal Cancer

Dual-energy SPEctral CT to Evaluate Response to New First-line Therapies in Patients With Metastatic Clear Cell REnal Cancer and the Association of Its Parameters With Molecular Alterations

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Enrollment

50 participants

Start Date

Sep 30, 2024

Study Type

OBSERVATIONAL

Conditions

Renal Cancer

Summary

To evaluate the utility of dual-energy spectral computed tomography (CT) scan in monitoring treatment in patients with metastatic clear cell carcinoma of the kidney. In particular, to analyze the use of spectral CT in patients who are candidates to receive first-line treatment based on combinations of immunotherapy and molecularly targeted drugs. In particular, the parameters derived from the use of this technology and their variation during therapy will be analyzed together with some possible molecular alterations highlighted by the analysis of the tumor tissue previously taken from the patient, relating them to the response to first-line therapy with immuno-combinations.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is evaluating whether a type of advanced CT scan (dual-energy spectral CT) can better predict how metastatic clear cell kidney cancer responds to first-line combination treatments (immunotherapy plus targeted therapy). **You may be eligible if...** - You are 18 or older - You have confirmed metastatic clear cell renal cell carcinoma (kidney cancer) - You have not yet received any treatment for your kidney cancer - You are scheduled to receive standard first-line combination treatment (immunotherapy + targeted therapy) - You have had a dual-energy spectral CT scan within 4 weeks of starting treatment - A stored tumor tissue sample is available for molecular analysis **You may NOT be eligible if...** - You have already received treatment for your kidney cancer - You do not have a stored tissue sample available - Your cancer is not the clear cell subtype Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(2)

Irccs Azienda Ospedaliero Universitario Di Bologna

Bologna, BO, Italy

Oncology Unit, IRCCS Azienda Ospedaliero Universitaria Bologna

Bologna, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06863857

Related Trials

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

NCT000268841 location

Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies

NCT011093945 locations

Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers

NCT069679611 location

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

NCT07227415109 locations

Video Education With Result Dependent dIsclosure

NCT052254281 location